Additional file 1 of Spatial intra-tumour heterogeneity and treatment-induced genomic evolution in oesophageal adenocarcinoma: implications for prognosis and therapy

Additional file 1: Table S1. Clinical information for the cohort. NSR, no sign of recurrence; OG, oesophago-gastric. Table S2. Sample information including estimated tumour cellularity, mutation count and tumour mutation burden (TMB; mutations/Mb). Table S3. Differences in signature proportions between shared and private mutation populations. Comparisons between continuous values used Student’s t-test and Fisher’s exact test for dichotomised data. p-values were corrected for multiple testing through fdr correction. Table S4. Detected clonal ClinVar variants in TP53 across the cohort. Table S5. Number of mutations assigned to individual clones. Table S6. Putative neoantigens identified in clones present in pre-treatment but not post-treatment samples.

附加文件1：表S1。本队列的临床信息。其中NSR（no sign of recurrence）指无复发迹象，OG（oesophago-gastric）指食管胃。
表S2。样本信息，包含预估肿瘤细胞占比、突变计数及肿瘤突变负荷（tumour mutation burden，TMB；突变数/兆碱基）。
表S3。共有突变群体与私有突变群体的特征占比差异。连续变量的组间比较采用学生t检验（Student’s t-test），二分类数据则采用Fisher精确检验（Fisher’s exact test）。针对多重检验，采用fdr（false discovery rate，错误发现率）校正P值。
表S4。本队列中检出的TP53基因克隆型ClinVar变异。
表S5。分配至各克隆的突变数。
表S6。在治疗前样本存在但治疗后样本缺失的克隆中检出的推定新抗原。